HUMA Humacyte, Inc
Price Chart
Executive Summary
Humacyte's Marketing Authorization Application (MAA) for its acellular tissue engineered vessel (Symvess) has been accepted by Israel's Ministry of Health for review, with a 180-working-day timeline due to prior FDA approval. This marks a key step in the company's planned international expansion of Symvess for arterial trauma repair.
Actionable Insight
Monitor for updates on the Israel MAA review outcome within the 180-working-day window, as approval could serve as a regulatory pathway template for other non-U.S. markets and catalyze further international submissions.
Key Facts
- Israel Ministry of Health accepted Humacyte's MAA for Symvess (ATEV) for arterial trauma repair.
- Review period set at 180 working days, accelerated due to existing FDA approval in the U.S.
- This is part of Humacyte's strategy to expand Symvess globally beyond the U.S.
- Symvess received FDA approval in December 2024 for extremity vascular trauma.
- Additional late-stage trials ongoing for AV access and peripheral artery disease.
Financial Impact
Potential expansion into international markets could significantly increase revenue base; exact financial impact depends on approval outcome and reimbursement.
Risk Factors
- Regulatory delays or rejection outside the U.S. despite FDA precedent.
- Commercial execution risk in scaling manufacturing and market adoption internationally.
- Dependence on third-party reimbursement for market uptake.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277834 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Institutional Cluster
| $1.07 awaiting T+5 | awaiting T+5 | — | $1.05 (−0.94%) |
|
Jun 11, 2026
3d ago
|
8-K
| $1.07 awaiting T+5 | awaiting T+5 | — | $1.05 (+1.40%) |
|
Jun 11, 2026
4d ago
|
Press Release
| $1.16 awaiting T+5 | awaiting T+5 | — | $1.05 (+9.05%) |
|
Jun 11, 2026
4d ago
|
Press Release
| $1.16 awaiting T+5 | awaiting T+5 | — | $1.05 (+9.05%) |
|
Jun 10, 2026
4d ago
|
Press Release
| $1.35 awaiting T+5 | awaiting T+5 | — | $1.05 (−21.85%) |
|
May 20, 2026
25d ago
|
Insider Cluster
| $1.02 $1.28 | ▲ +25.49% | ▲ +23.89% | $1.05 (+3.43%) |
|
May 13, 2026
4w ago
|
Press Release
| $1.13 $0.8250 | ▼ −26.99% | ▼ −25.83% | $1.05 (−6.64%) |
|
May 8, 2026
5w ago
|
Press Release
| $1.06 $1.00 | ▼ −5.66% | ▼ −7.12% | $1.05 (−0.47%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $0.6590 $0.8480 | ▲ +28.68% | ▲ +27.60% | $1.05 (+60.09%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $0.8500 $0.5750 | ▼ −32.35% | ▼ −28.79% | $1.05 (+24.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access